Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
R-EPOCH + ibrutinib
- Development stage
- Unknown
- Lead developer
- Pharmacyclics
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Administration
- Intravenous, Oral
01
Overview
R-EPOCH + ibrutinib is a combination regimen used primarily in the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including AIDS-related lymphomas. The R-EPOCH regimen consists of rituximab (a monoclonal antibody targeting CD20), etoposide (a topoisomerase II inhibitor), prednisone (a corticosteroid), vincristine (a microtubule inhibitor), cyclophosphamide (an alkylating agent), and doxorubicin (an anthracycline antibiotic). Ibrutinib is a small molecule Bruton’s tyrosine kinase inhibitor that blocks B-cell receptor signaling pathways critical for the survival and proliferation of malignant B cells. The addition of ibrutinib to R-EPOCH aims to enhance antitumor activity by combining cytotoxic chemotherapy with targeted inhibition of B-cell signaling[1][3][5][6].
- Brand names
- ToposarOncovinCytoxanAdriamycin
- Other names
- dose-adjusted EPOCH-R plus rituximab and ibrutinib
02
Targets
BMX (Bone Marrow Tyrosine Kinase X-linked)BTK (Bruton tyrosine kinase)CD20 (B-lymphocyte antigen CD20)DNAGR (Glucocorticoid receptor)ITK (Interleukin 2-inducible T-cell kinase)TOP2A (DNA topoisomerase II)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on R-EPOCH + ibrutinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on R-EPOCH + ibrutinib.